A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment

Autor:	Bonne Biesma, Egbert F. Smit, Fmnh Schramel, Hendricus Groen, Floris M Wachters, Pieter E. Postmus, Jos A. Stigt
Jazyk:	angličtina
Rok vydání:	2005
Předmět:	Male Oncology Cancer Research Lung Neoplasms medicine.medical_treatment carcinoma IFOSFAMIDE QUALITY-OF-LIFE Carcinoma Non-Small-Cell Lung Clinical Studies Antineoplastic Combined Chemotherapy Protocols docetaxel irinotecan PLATINUM Ifosfamide second-line chemotherapy PREVIOUSLY TREATED PATIENTS clinical trial Middle Aged phase II Docetaxel Toxicity Female Taxoids therapeutics CLINICAL-TRIALS medicine.drug Adult medicine.medical_specialty Adolescent CONTAINING CHEMOTHERAPY REGIMENS Disease-Free Survival CISPLATIN Internal medicine SUPPORTIVE CARE medicine Humans Lung cancer neoplasms METAANALYSIS Aged Cisplatin Chemotherapy business.industry medicine.disease Surgery Irinotecan non-small-cell lung Camptothecin business
Zdroj:	British Journal of Cancer British Jounal of Cancer, 92(1), 15-20. Nature Publishing Group
ISSN:	0007-0920
DOI:	10.1038/sj.bjc.6602268
Popis:	Response rate and toxicity of second-line therapy with docetaxel (75 mg m(-2)) or docetaxel, irinotecan, and lenogastrim (60 mg m(-2), 200 mg m(-2), and 150 mug m(-2) day(-1), respectively) were compared in 108 patients with stage IIIb - IV non-small-cell lung cancer. Addition of irinotecan to docetaxel does not improve response rate, and increases gastrointestinal toxicity.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73d5e18ef46404bd59978ab57f2f0661 https://doi.org/10.1038/sj.bjc.6602268 Zobrazit plný text záznamu Plný text ve formátu PDF